LTRN (Lantern Pharma) EPS (Basic): $-1.45 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTRN Lantern Pharma Inc LTRN
33 GF Score
Price $2.98
! 2 Warning Signs
View Full Analysis

What is Lantern Pharma EPS (Basic)?

Lantern Pharma LTRN -0.34% 33 EPS (Basic) is $-1.45 as of Mar. 2026. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Lantern Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.30. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.45.

Lantern Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.45.

Lantern Pharma's EPS without NRI for the three months ended in Mar. 2026 was $-0.30. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.45.

During the past 3 years, the average EPS without NRI Growth Rate was -6.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Lantern Pharma's highest 3-Year average EPS without NRI Growth Rate was -2.40% per year. The lowest was -59.60% per year. And the median was -19.50% per year.

Lantern Pharma  (NAS:LTRN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lantern Pharma EPS (Basic) Related Terms

Lantern Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lantern Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantern Pharma EPS (Basic) Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -1.13 -1.31 -1.47 -1.93 -1.57

Lantern Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.40 -0.39 -0.36 -0.30
LTRN
33GF Score
Lantern Pharma Inc LTRN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantern Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lantern Pharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-17.119-0)/10.898
=-1.57

Lantern Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.329-0)/11.253
=-0.30

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-1.45 mean?
Lantern Pharma (LTRN) has a EPS (Basic) of $-1.45 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lantern Pharma and its competitors.
Is Lantern Pharma's EPS (Basic) too high?
Lantern Pharma's current EPS (Basic) is $-1.45. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's EPS (Basic) compare to PDSB and AURX?
Lantern Pharma's EPS (Basic) of $-1.45 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lantern Pharma and its competitors. Lantern Pharma's current EPS (Basic) is $-1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current EPS (Basic) of $-1.45. The current EPS (Basic) is $-1.45. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current EPS (Basic) is $-1.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lantern Pharma Business Description

Address 1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score

Get the complete analysis for LTRN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price